Vitae Pharmaceuticals (VTAE) Reports In-Line Q4 Loss of 40c/Share

Vitae Pharmaceuticals (NASDAQ: VTAE) reported Q4 EPS of ($0.40), in-line with the analyst estimate of ($0.40). Revenue for the quarter came in at $161.7 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c